30680679|t|Pharmacological Management of Dementia with Lewy Bodies.
30680679|a|Dementia with Lewy bodies (DLB) is a complex disease that involves a variety of cognitive, behavioral and neurological symptoms, including progressive memory loss, visual hallucinations, parkinsonism, cognitive fluctuations and rapid eye movement sleep behavior disorder (RBD). These symptoms may appear in varying combinations and levels of severity in each patient who is seen in the clinic, making diagnosis and treatment a challenge. DLB is the third most common of all the neurodegenerative diseases behind both Alzheimer's disease and Parkinson's disease (PD). The median age of onset for DLB (76.3 years) is younger than that seen in PD dementia (81.4 years). New pathological studies have shown that most DLB patients have variable amounts of Alzheimer's changes in their brains, explaining the wide variability in this disease's clinical presentation and clinical course. This review discusses the three cholinesterase inhibitors that have been shown to be effective in managing the cognitive and behavioral symptoms of DLB: rivastigmine, galantamine and donepezil. Memantine is able to improve clinical global impression of change in those with mild to moderate DLB. Levodopa can treat the parkinsonism of some DLB patients, but the dose is often limited due to the fact that it can cause agitation or worsening of visual hallucinations. A recent phase 2 clinical trial showed the benefit of zonisamide when it is added as an adjunct to levodopa for treating DLB parkinsonism. While atypical antipsychotic drugs may not always be helpful as monotherapy in managing the agitation associated with DLB, low doses of valproic acid can be effective when added as an adjunct to drugs like quetiapine. Pimavanserin may prove to be a useful treatment for psychosis in DLB patients, but like other antipsychotic drugs that are used in dementia patients, there is a small increased risk of mortality. RBD, which is a common core clinical feature of DLB, can be managed with either melatonin or clonazepam. Two agents targeting alpha-synuclein (NPT200-11 and ambroxol) currently hold promise as disease-modifying therapies for DLB, but they are yet to be tested in clinical trials. An agent (E2027) that offers hope of neuroprotection by increasing central cyclic guanosine monophosphate (cGMP) levels is currently being examined in clinical trials in DLB patients.
30680679	30	55	Dementia with Lewy Bodies	Disease	MESH:D020961
30680679	57	82	Dementia with Lewy bodies	Disease	MESH:D020961
30680679	84	87	DLB	Disease	MESH:D020961
30680679	208	219	memory loss	Disease	MESH:D008569
30680679	221	242	visual hallucinations	Disease	MESH:D006212
30680679	244	256	parkinsonism	Disease	MESH:D010302
30680679	285	327	rapid eye movement sleep behavior disorder	Disease	MESH:D020187
30680679	329	332	RBD	Disease	
30680679	416	423	patient	Species	9606
30680679	495	498	DLB	Disease	MESH:D020961
30680679	535	561	neurodegenerative diseases	Disease	MESH:D019636
30680679	574	593	Alzheimer's disease	Disease	MESH:D000544
30680679	598	617	Parkinson's disease	Disease	MESH:D010300
30680679	619	621	PD	Disease	MESH:D010300
30680679	652	655	DLB	Disease	MESH:D020961
30680679	698	709	PD dementia	Disease	MESH:D010300
30680679	770	773	DLB	Disease	MESH:D020961
30680679	774	782	patients	Species	9606
30680679	808	817	Alzheimer	Disease	MESH:D000544
30680679	1086	1089	DLB	Disease	MESH:D020961
30680679	1091	1103	rivastigmine	Chemical	MESH:D000068836
30680679	1105	1116	galantamine	Chemical	MESH:D005702
30680679	1121	1130	donepezil	Chemical	MESH:D000077265
30680679	1132	1141	Memantine	Chemical	MESH:D008559
30680679	1229	1232	DLB	Disease	MESH:D020961
30680679	1234	1242	Levodopa	Chemical	MESH:D007980
30680679	1257	1269	parkinsonism	Disease	MESH:D010302
30680679	1278	1281	DLB	Disease	MESH:D020961
30680679	1282	1290	patients	Species	9606
30680679	1356	1365	agitation	Disease	MESH:D011595
30680679	1382	1403	visual hallucinations	Disease	MESH:D006212
30680679	1459	1469	zonisamide	Chemical	MESH:D000078305
30680679	1504	1512	levodopa	Chemical	MESH:D007980
30680679	1526	1542	DLB parkinsonism	Disease	MESH:C566823
30680679	1636	1645	agitation	Disease	MESH:D011595
30680679	1662	1665	DLB	Disease	MESH:D020961
30680679	1680	1693	valproic acid	Chemical	MESH:D014635
30680679	1750	1760	quetiapine	Chemical	MESH:D000069348
30680679	1762	1774	Pimavanserin	Chemical	MESH:C510793
30680679	1814	1823	psychosis	Disease	MESH:D011618
30680679	1827	1830	DLB	Disease	MESH:D020961
30680679	1831	1839	patients	Species	9606
30680679	1893	1901	dementia	Disease	MESH:D003704
30680679	1902	1910	patients	Species	9606
30680679	1958	1961	RBD	Disease	
30680679	2006	2009	DLB	Disease	MESH:D020961
30680679	2038	2047	melatonin	Chemical	MESH:D008550
30680679	2051	2061	clonazepam	Chemical	MESH:D002998
30680679	2084	2099	alpha-synuclein	Gene	6622
30680679	2101	2110	NPT200-11	Chemical	MESH:C000654389
30680679	2115	2123	ambroxol	Chemical	MESH:D000551
30680679	2183	2186	DLB	Disease	MESH:D020961
30680679	2248	2253	E2027	Chemical	-
30680679	2313	2343	cyclic guanosine monophosphate	Chemical	MESH:D006152
30680679	2345	2349	cGMP	Chemical	MESH:D006152
30680679	2408	2411	DLB	Disease	MESH:D020961
30680679	2412	2420	patients	Species	9606
30680679	Negative_Correlation	MESH:D000068836	MESH:D020961
30680679	Negative_Correlation	MESH:D007980	MESH:D020961
30680679	Association	MESH:D020961	6622
30680679	Negative_Correlation	MESH:D014635	MESH:D011595
30680679	Negative_Correlation	MESH:D007980	MESH:C566823
30680679	Negative_Correlation	MESH:D007980	MESH:D010302
30680679	Positive_Correlation	MESH:D007980	MESH:D011595
30680679	Negative_Correlation	MESH:C000654389	6622
30680679	Negative_Correlation	MESH:C510793	MESH:D020961
30680679	Negative_Correlation	MESH:D005702	MESH:D020961
30680679	Negative_Correlation	MESH:D000078305	MESH:C566823
30680679	Negative_Correlation	MESH:C510793	MESH:D003704
30680679	Association	MESH:D000069348	MESH:D014635
30680679	Negative_Correlation	MESH:D000077265	MESH:D020961
30680679	Association	MESH:C000654389	MESH:D020961
30680679	Negative_Correlation	MESH:C510793	MESH:D011618
30680679	Positive_Correlation	MESH:D007980	MESH:D006212
30680679	Negative_Correlation	MESH:D000551	MESH:D020961
30680679	Cotreatment	MESH:D000078305	MESH:D007980
30680679	Negative_Correlation	MESH:D008559	MESH:D020961
30680679	Negative_Correlation	MESH:D002998	MESH:D020961

